| Source: |
| Type: |
| Polo-like kinase 1 (PLK-1) is a mitotic serine/threonine kinase and high-value cancer target. It is commonly upregulated in proliferative malignancies and supports G2/M progression, spindle formation, chromosome segregation, cytokinesis, DNA-damage recovery, and survival of genomically unstable tumor cells. Inhibition of PLK1 can induce mitotic arrest, apoptosis, and sensitization to chemotherapy or radiotherapy. Clinical development has been challenging due to toxicity and limited single-agent efficacy with earlier inhibitors, but newer agents such as onvansertib show renewed promise, particularly in RAS/KRAS-mutant metastatic colorectal cancer. |
| 8177- | Las, | Lasiokaurin Regulates PLK1 to Induce Breast Cancer Cell G2/M Phase Block and Apoptosis |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 6451- | SAO, | α-Santalol functionalized chitosan nanoparticles as efficient inhibitors of polo-like kinase in triple negative breast cancer |
| - | vitro+vivo, | BC, | MDA-MB-231 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1492 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid